Skip to main content

GC511B CAR-T Cell

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer

  • RegistryNCT07249879
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed/Refractory Small Cell Lung Cancer
  • SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
How GC511B CAR-T Cell worksNCT072498791 min

What the film says

Read the transcript

Small cell lung cancer responds to chemotherapy, then almost always returns within months, and second-line options are weak.

The idea: a CAR T cell for a target that small cell lung cancer displays and normal adult tissue mostly hides.

That target is DLL3, a protein on the surface of most small cell lung cancers. At the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing, a patient's T cells are engineered with a receptor for DLL3 and returned in one infusion after conditioning chemotherapy. Doses rise cautiously, one patient at a time at first.

A first study in people, for relapsed or refractory disease whose tumor tests positive. Ning Li leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07249879

    DLL3 on most SCLC, minimal normal adult expression; Autologous lentiviral CAR T; "dual CAR-T"; single IV infusion; Accelerated titration then BOIN escalation; first patients staggered; First-in-human; DLL3+ r/r SCLC; Ning Li

The drug

What is being tested.

This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that GC511B.Administration of GC511B CAR T-Cells a dose levels of DL1,DL2,DL3 and DL4 are administrated for each trial participants.Single IV infusion.

This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants. this study consists of two parts: dose escalation and dose expansion: Dose Escalation: This part consists of two stages:Stage 1: Accelerated titration design to explore the effective starting dose;Stage 2: Bayesian optimal interval (BOIN) design to explore the MAD/MTD.The BOIN design will start with aDL1 as determined in Stage 1 and continue until either 9 trial participants have been enrolled at a single dose level (DL) or the total number of trial participants reaches 11.Starting with BOIN stage DL3, the first and second trial participants were reinfused at least 2 weeks apart.During the dose-escalation phase, following each dose level (DL) and/or scheduled infusion time point, the Safety Review Committee (SRC) will evaluate all adverse events (AEs), serious adverse events (SAEs), laboratory safety data from subjects in the DLT observation period, as well as all other relevant available data, to determine the next DL to be explored and/or dosing schedule and to provide recommendations for subsequent study conduct.

Dose expansion : The dose expansion phase will be initiated at the defined RDE to further investigate the safety, feasibility, CK, immunogenicity, PD, and preliminary antitumor activity of GC511B monotherapy and/or combination therapy. Up to 4 expansion cohorts may be opened to evaluate specific DLs and indications with up to 20 response-evaluable trial participants included in each cohort.

The study

How the trial runs.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • 1.Trial articipant must be ≥ 18 years and ≤75 years of age at the time of signing the ICF.
  • Type of Subjects and Disease Characteristics
  • 2.ECOG performance status 0-2.
  • 3.Life expectancy ≥ 12 weeks.
  • 4.At least 1 TL meeting RECIST v1.1 at screening. Tumor assessment by CT scan or MRI must be performed within 28 days prior to apheresis.
  • A lesion can be considered TL if the lesion previously subjected to radiotherapy has a clear boundary, is measurable as per RECIST v1.1, and has clear progression during or after the latest treatment;

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.